COVID-19 Rapid Test Kit IgG + IgM (Colloidal Gold) (A122152)

Not known Details About Rapid Detection of IgM Antibodies against the SARS-CoV-2

1. Easy to collect samplessimple operation without professional equipment. 2.  The Latest Info Found Here  are offered in 15 minutes, and the test outcomes are clearly visible. 3. Convenient transport and low rate, greater precision. 4. Suitable for large-scale fast screening.

SARS-CoV-2 Antigen Rapid Test Kit - Goffin Molecular Technologies

The Fda (FDA) has actually alerted customers to stop utilizing an unauthorized COVID-19 at-home fast test and antibody test over issues that the kits may produce incorrect results. The packages, produced by Lepu Medical Innovation, were dispersed to drug stores to be sold to customers for at-home screening and provided through direct sales in spite of not having FDA permission.

The FDA stated it has "severe issues about the performance" of both tests. Health care suppliers who utilized the antigen test within the last two weeks and think an unreliable result are advised to retest clients utilizing a various kit. Those who utilized the antibody test just recently and believe a false result are also instructed to retest clients utilizing a different kit.

SARS-Co, V-2 Antigen Fast Test Kit (Colloidal Gold)20 Tests/box (1Test/bag 20 Bags),40 Tests/box (1Test/bag 40 Bags)planned USEFor in vitro qualitative detection of SARS-Co, V-2 nucleocapsidantigen in nasal (NS) swab specimens directly from people who are thought of COVID-19 by their health care company within the very first 5 days after beginning of symptoms.

SARS-CoV-2 ANTIGEN RAPID TEST KIT LOT OF 100

Things about Annex № 2 to items I, 4.1.2

Severe intense respiratory syndrome coronavirus 2 (SARS-Co, V-2, or 2019-n, Co, V) is an enveloped non-segmented positive-sense RNA virus. It is the cause of coronavirus disease (COVID-19), which is infectious inhumans. SARS-Co, V-2 has several structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N). The antigen is generally noticeable in upper breathing samples during the acute stage of infection.

Favorable outcomes do not eliminate a bacterial infection or co-infection with other infections. The agent found may not be the certain cause of illness. Negative outcomes ought to be treated as presumptive, which do not rule out SARS-Co, V-2 infection and should not be utilized as the sole basis for treatment or client management decisions, consisting of infection control decisions.